Clinical trial
An Observational Study to Assess the Effectiveness of Intravitreal Aflibercept in Routine Clinical Practice tn Patients With Visual Impairment Due to Diabetic Macular Oedema (DMO)
NCT02850263 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Study to Assess the Effectiveness of Intravitreal Aflibercept in Routine Clinical Practice tn Patients With Visual Impairment Due to Diabetic Macular Oedema (DMO)
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 5, 2016
- Completion date
- November 23, 2020
- Enrollment
- 750 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.